drugset / Trial / NCT01217008
Safety Study of GRNOPC1 in Spinal Cord Injury
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety of GRNOPC1 administered at a single time-point between 7 and 14 days post injury, inclusive, to patients with neurologically complete spinal cord injuries (SCI).
Timeline
- Start
- 2010-10
- Primary completion
- 2013-07
- Completion
- 2013-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GRNOPC1 | Cell therapy | 2e+06 cells | — |